Alkermes, Inc.

NASDAQ: ALKS
$14.12
+$0.10 (+0.7%)
Closing price April 3, 2020
Friday's top analyst upgrades, downgrades and initiations included Alkermes, Aurora Cannabis, BlackRock, Duke Energy, Nvidia, Ralph Lauren, SunPower, Veeva Systems and Yelp.
Lee Jackson
Biogen and Alkermes have announced that the FDA approved Vumerity for the treatment of relapsing forms of multiple sclerosis.
Chris Lange
Alkermes shares made a handy gain on Monday after the firm announced that it would be expanding its New Drug Application for ALKS 3831 to encompass the treatment of bipolar I disorder in addition to...
Chris Lange
The top analyst upgrades, downgrades and initiations on Monday included Agilent Technologies, Amazon.com, American Water Works, Crocs, Deere, General Electric, Gilead Sciences, Slack and Teva...
Jon C. Ogg
The top analyst upgrades, downgrades and initiations seen on Friday included Alkermes, Apple, Canada Goose, FireEye, J.Jill, Kraft Heinz, Uber Technologies and Vonage.
Jon C. Ogg
The top analyst upgrades, downgrades and initiations seen on Wednesday included Alkermes, Alphabet, Apple, ConocoPhillips, FireEye, Lyft, McDonald's, Royal Bank of Scotland, Seagate Technology and...
Jon C. Ogg
The top analyst upgrades, downgrades and initiations seen on Wednesday included Apple, Baker Hughes, Biogen, FedEx, Intel, Micron Technology, Roku and Shake Shack.
Jon C. Ogg
Alkermes shares dropped early on Friday after the company anncounced the results from its most recent meeting with the U.S. Food and Drug Administration.
Chris Lange
The top analyst upgrades, downgrades and other research calls from Tuesday include Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts and Zillow.
Jon C. Ogg
The top analyst upgrades, downgrades and other research calls from Wednesday include Alkermes, Cigna, International Paper, Medtronic, Tesla and Western Digital.
Lee Jackson
The top analyst upgrades, downgrades and other research calls from Friday included AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp and Sarepta Therapeutics.
Lee Jackson
Shares of Alkermes saw a handy gain to start out the week after the FDA made a critical decision about its treatment for major depressive disorder.
Chris Lange
Alkermes saw its shares drop early on Monday after the company announced that it received a Refusal to File letter from the FDA.
Chris Lange
The top analyst upgrades, downgrades and other research calls from Thursday include Alkermes, ArQule, Bluebird Bio, Cognizant Technology Solutions, Ecolab, KLA-Tencor, Pandora Media, Verisk Analytics...
Jon C. Ogg
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
Chris Lange